Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BMS-986301 by Bristol-Myers Squibb for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
BMS-986301 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
BMS-986301 by Bristol-Myers Squibb for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
BMS-986301 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Head And Neck Squamous Cell Carcinoma...
BMS-986301 by Bristol-Myers Squibb for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
BMS-986301 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....
BMS-986301 by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
BMS-986301 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer. According to...
BMS-986301 by Bristol-Myers Squibb for Renal Cell Carcinoma: Likelihood of Approval
BMS-986301 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Renal Cell Carcinoma. According to GlobalData,...
BMS-986301 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
BMS-986301 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
BMS-986301 by Bristol-Myers Squibb for Melanoma: Likelihood of Approval
BMS-986301 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Melanoma. According to GlobalData, Phase I...